AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

CEO David Cordani highlighted Cigna's full-year revenue growth of $247 billion, a 27% increase, alongside adjusted EPS of $27.33, which fell short of expectations. He reaffirmed the company's ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Thank you for standing by for the Cigna Group's fourth quarter 2024 results review. At this time, all callers are in a listen ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The global online pharmacy market size was valued at USD 112.46 billion in 2024 and is projected to reach from USD 131.65 billion in 2025 to USD 543.36 billion by 2033, growing at a CAGR of 17.06% ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Cigna Group (NYSE: CI) reported its performance in the fourth quarter of 2024, with total revenues reaching $65.6 billion.